Ken Takeuchi

Kashiwanoha, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 53 publications

Efficacy and Safety of Switching From Intravenous to Subcutaneous Vedolizumab in Japanese Patients With Ulcerative Colitis: A Study Focusing on Injection-Site Reactions.

Efficacy and Safety of Switching From Intravenous to Subcutaneous Vedolizumab in Japanese Patients With Ulcerative Colitis: A Study Focusing on Injection-Site Reactions.

Journal: JGH open : an open access journal of gastroenterology and hepatology

Published: January 06, 2026

Real-World Efficacy of Ustekinumab versus Vedolizumab for Ulcerative Colitis: Differences between Short- and Long-Term Outcomes Based on Endoscopic Remission.

Real-World Efficacy of Ustekinumab versus Vedolizumab for Ulcerative Colitis: Differences between Short- and Long-Term Outcomes Based on Endoscopic Remission.

Journal: Inflammatory intestinal diseases

Published: November 28, 2025

Development and Validation of a Urinary Exosomal miRNA Diagnostic Panel for Early Detection of Esophageal Cancer.

Development and Validation of a Urinary Exosomal miRNA Diagnostic Panel for Early Detection of Esophageal Cancer.

Journal: Cancer science

Published: July 26, 2025

Efficacy and safety of subcutaneous guselkumab in East Asian participants with moderately to severely active Crohn's disease: subgroup analysis of the Phase 3 GRAVITI study.

Efficacy and safety of subcutaneous guselkumab in East Asian participants with moderately to severely active Crohn's disease: subgroup analysis of the Phase 3 GRAVITI study.

Journal: Intestinal research

Published: June 23, 2025

Lung cancer with MET exon 14 skipping mutation presenting with a crazy-paving appearance.

Lung cancer with MET exon 14 skipping mutation presenting with a crazy-paving appearance.

Journal: American journal of respiratory and critical care medicine

Published: June 10, 2025

Once-Daily Oral Ozanimod for Japanese Patients With Ulcerative Colitis: Results From the Phase 2/3 J-True North Study.

Once-Daily Oral Ozanimod for Japanese Patients With Ulcerative Colitis: Results From the Phase 2/3 J-True North Study.

Journal: Gastro hep advances

Published: May 29, 2025

Risankizumab efficacy and safety based on prior inadequate response or intolerance to advanced therapy: post hoc analysis of the INSPIRE and COMMAND phase 3 studies.

Risankizumab efficacy and safety based on prior inadequate response or intolerance to advanced therapy: post hoc analysis of the INSPIRE and COMMAND phase 3 studies.

Journal: Journal of Crohn's & colitis

Published: January 13, 2025

Designing Effective Protocol-Based Pharmacotherapy Management: Assessment of the Development Processes and Outcomes in Inflammatory Bowel Disease Care Prescription Management.

Designing Effective Protocol-Based Pharmacotherapy Management: Assessment of the Development Processes and Outcomes in Inflammatory Bowel Disease Care Prescription Management.

Journal: Pharmacy (Basel, Switzerland)

Published: December 27, 2024

Prevalence and predictability of the Chicago Classification of Pouchitis in ulcerative colitis: a multicenter study in Japan.

Prevalence and predictability of the Chicago Classification of Pouchitis in ulcerative colitis: a multicenter study in Japan.

Journal: Journal of gastroenterology

Published: December 20, 2024

Efficacy and safety of etrasimod in Japanese patients with ulcerative colitis: results from a phase 2 dose-ranging study.

Efficacy and safety of etrasimod in Japanese patients with ulcerative colitis: results from a phase 2 dose-ranging study.

Journal: Intestinal research

Published: December 17, 2024

Real-World Effectiveness and Safety of Vedolizumab in Patients ≥ 70 Versus < 70 Years With Ulcerative Colitis: Multicenter Retrospective Study.

Real-World Effectiveness and Safety of Vedolizumab in Patients ≥ 70 Versus < 70 Years With Ulcerative Colitis: Multicenter Retrospective Study.

Journal: Journal of gastroenterology and hepatology

Published: September 19, 2024

The duration of prior anti-tumor necrosis factor agents is associated with the effectiveness of vedolizumab in patients with ulcerative colitis: a real-world multicenter retrospective study.

The duration of prior anti-tumor necrosis factor agents is associated with the effectiveness of vedolizumab in patients with ulcerative colitis: a real-world multicenter retrospective study.

Journal: Intestinal research

Published: August 09, 2024

Showing 1-12 of 53

Last Updated: 09/26/2026